81.8%
A2 Biotherapeuticsadvanced solid malignancyBASECAMP-1logic-gated Tmod chimeric antigen receptor T-cell therapiesBASECAMP-1Tempus AIadvanced solid malignancies
…y for rare molecular subpopulations. To address this challenge, A2 Biotherapeutics developed BASECAMP-1 ( NCT04981119), a non-interventional maste…